SIX · ROP.SW
Roche Holding AG
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
Loading market information…
NASDAQ · PHVS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pharvaris N.V.’s quoted price sits in the upper half of its reported 52-week range, 22.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pharvaris N.V.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pharvaris N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.66+11.53% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$0.85-28.79% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 11 contributors · Median target $62.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
CHF 132.30+CHF 3.08 (+2.38%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 1.53% below the high.
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$30.53-$0.41 (-1.33%)
Vera Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.53% below the high.
$8.52+$0.15 (+1.79%)
BioCryst Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
$12.13-$0.13 (-1.06%)
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.16% below the high.
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
